Marcos González

Marcos González publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Marcos González sits on this spectrum.

Marcos González D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Marcos González sits on this spectrum.

Overview

Best Publications

• Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

  J J M van Dongen;A W Langerak;M Brüggemann;P A S Evans

  2962
  Citations

• Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program

  J Gabert;E Beillard;V H J van der Velden;W Bi

  2222
  Citations

• Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

  Xose S. Puente;Magda Pinyol;Víctor Quesada;Laura Conde

  1857
  Citations

• Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.

  Víctor Quesada;Laura Conde;Neus Villamor;Gonzalo R Ordóñez

  1225
  Citations

• Non-coding recurrent mutations in chronic lymphocytic leukaemia

  Xose S. Puente;Silvia Beà;Rafael Valdés-Mas;Neus Villamor

  1012
  Citations

• Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.

  Miguel A. Sanz;Francesco Lo Coco;Guillermo Martı́n;Giuseppe Avvisati

  874
  Citations

• Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

  J Flores-Montero;L Sanoja-Flores;B Paiva;N Puig

  694
  Citations

• Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group

  Miguel A. Sanz;Guillermo Martín;Marcos González;Angel León

  641
  Citations

• A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group.

  Miguel A. Sanz;Guillermo Martı́n;Consuelo Rayón;Jordi Esteve

  607
  Citations

• Perioperative patient outcomes in the African Surgical Outcomes Study: a 7-day prospective observational cohort study

  Bruce M Biccard;Thandinkosi E Madiba;Hyla-Louise Kluyts;Dolly M Munlemvo

  517
  Citations

• Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.

  Pongers-Willemse Mj;Seriu T;Stolz F;d'Aniello E

  510
  Citations

• Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

  Joaquin Martinez-Lopez;Juan J. Lahuerta;François Pepin;Marcos González

  476
  Citations

• Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification.

  Jesús F. San Miguel;Marı́a B. Vidriales;Consuelo López-Berges;Joaquı́n Dı́az-Mediavilla

  468
  Citations

• Primary Plasma Cell Leukemia: Clinical, Immunophenotypic, DNA Ploidy, and Cytogenetic Characteristics

  R. Garcı́a-Sanz;A. Orfão;M. González;M.D. Tabernero

  445
  Citations

• Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.

  Javier de Serna;Pau Montesinos;Edo Vellenga;Chelo Rayón

  433
  Citations

• Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors

  Pau Montesinos;Juan M. Bergua;Edo Vellenga;Chelo Rayón

  418
  Citations

• Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification

  A. López-Guillermo;J. Cid;A. Salar;A. López

  403
  Citations

• Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1 and ATM mutations in chronic lymphocytic leukemia

  Ferran Nadeu;Julio Delgado;Cristina Royo;Tycho Baumann

  379
  Citations

• Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants.

  Sı́lvia Beà;Maria Ribas;Jesús M. Hernández;Francesc Bosch

  356
  Citations

• A primitive hematopoietic cell is the target for the leukemic transformation in human Philadelphia-positive acute lymphoblastic leukemia

  C Cobaleda;N Gutiérrez-Cianca;J Pérez-Losada;T Flores

  339
  Citations